Last updated: February 24, 2026
What Is NDC 72603-0414?
NDC 72603-0414 corresponds to Lenvatinib mesylate, marketed under the brand name Lenvima. It is an oral kinase inhibitor used primarily for thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma.
Market Size and Demand Dynamics
Key Therapeutic Areas
- Thyroid Cancer: First approved in 2015. The U.S. market size conservatively estimates approximately 55,000 cases annually (American thyroid Association, 2022).
- Hepatocellular Carcinoma (HCC): Estimated at 42,000 new cases in 2022 in the U.S. (American Cancer Society, 2022).
- Renal Cell Carcinoma: About 78,000 new cases annually (National Cancer Institute, 2022).
Market Penetration
Lenvatinib faces competition from other tyrosine kinase inhibitors (TKIs) such as sorafenib, sorafenib, cabozantinib, and pazopanib. Its adoption depends heavily on regulatory approvals, reimbursement policies, and cumulative clinical evidence.
Sales Estimates
- 2022 U.S. Sales: Estimated at $600 million according to IQVIA data.
- Global Sales: Projected at approximately $1.2 billion in 2022, with growth potential in Europe, Asia-Pacific, and emerging markets.
Pricing Analysis
Current Pricing Structure
-
Average Wholesale Price (AWP): Around $12,000 for a 30-day supply (28 tablets of 4 mg or 8 mg strength). A, retail prices range from $11,500 to $13,000.
-
Reimbursement & Payer Policies: Payers negotiate discounts averaging 20-30%, reducing the net price to approximately $8,500 to $10,000.
Competitive Pricing Comparison
| Drug |
Indications |
30-day Wholesale Price |
Estimated Net Price (after discounts) |
| Lenvatinib (72603-0414) |
Thyroid, HCC, RCC |
$12,000 |
$8,500 - $10,000 |
| Sorafenib |
HCC, renal cell, thyroid |
$11,500 |
$8,100 - $10,200 |
| Cabozantinib |
RCC, HCC |
$13,000 |
$9,100 - $10,400 |
Price Trends
- Prices have remained relatively stable since 2018, with marginal reductions driven by payer negotiations and increased competition.
- Future price adjustments will depend on patent exclusivity status, biosimilar entry, and generic drug development.
Market Entry and Competitive Trends
Patent and Exclusivity
- Original patent expiration was in 2025; patent challenges and patent extensions could influence pricing strategies.
- Biosimilar or generic versions could enter by 2027-2028 if patent challenges are successful or if patents are not extended.
Regulatory and Market Expansion
- Regulatory Approvals: The drug is approved in the U.S., EU, Japan, and other markets.
- Market Expansion: Emerging markets in Asia-Pacific and Latin America represent growth opportunities. Enrollment in clinical trials for additional indications may further expand market access.
Price Projection (Next 3-5 Years)
| Year |
Estimated Global Sales |
Price Range (30-day supply) |
Market Drivers |
| 2023 |
$1.3 billion |
$11,500 - $13,000 |
Increased adoption; new indications |
| 2024 |
$1.4 billion |
$11,500 - $13,000 |
Patent status clarity; new approvals |
| 2025 |
$1.5 billion |
$11,500 - $13,000 |
Potential patent expiry; biosimilars |
| 2026 |
$1.6 billion |
$10,500 - $12,500 (possible discounts) |
Biosimilar entry begins; price competition |
| 2027 |
$1.7 billion |
$10,000 - $12,000 |
Dominance of biosimilars, volume growth |
Prices decline in the years following patent expiry due to biosimilar and generic competition. Sales growth is driven by expanded indications and markets.
Key Market Risks
- Patent Challenges: Uncertainty around patent extensions could accelerate biosimilar entry.
- Competitive Drugs: Emergence of alternative treatments with better safety profiles or efficacy.
- Pricing Negotiations: Increasing push for value-based pricing could pressure net prices.
Key Takeaways
- NDC 72603-0414 (Lenvatinib) is a mature product with stable pricing and substantial market share.
- U.S. sales primarily driven by thyroid cancer, HCC, and RCC indications.
- Wholesale prices are approximately $12,000, with net prices around $8,500 to $10,000 after discounts.
- Future revenue growth hinges on new indications, market expansion, and patent status.
- Biosimilar competition expected by 2027-2028 could reduce prices by 15-20%.
FAQs
1. How does Lenvatinib compare with other TKIs in efficacy?
Lenvatinib has demonstrated non-inferior or superior efficacy in specific indications such as thyroid cancer; comparative effectiveness varies by tumor type.
2. What factors could influence the price reduction of Lenvatinib?
Biosimilar entry, patent expiry, competitive pressure, and payer negotiations.
3. Are there ongoing clinical trials for new indications?
Yes. Trials are ongoing for combinations with immunotherapies and additional tumor types, which could affect future market dynamics.
4. What are the primary risks to market growth?
Patent challenges, generic biosimilar competition, and regulatory hurdles in expanding indications.
5. What is the potential for global market growth?
Significant, especially in emerging markets, contingent on regulatory approvals, pricing policies, and healthcare infrastructure.
References
[1] American Cancer Society. (2022). Cancer facts & figures 2022.
[2] American Thyroid Association. (2022). Thyroid cancer statistics.
[3] IQVIA. (2022). Commercial Pharmacy Trends Data.
[4] National Cancer Institute. (2022). Cancer statistics.
